Skip to: Content
Skip to: Site Navigation
Skip to: Search

SUNDAY, NOVEMBER 8, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter


0

Drug Companies Hide Data From Docs

Edited info could mislead those prescribing meds

Share

(Newser) – Pharmaceutical companies aren't as upfront with doctors as they are with the government about their new products, a study finds. Though drug companies must provide the FDA with all of the data from clinical trials, related papers published in medical journals were found to omit info from 20% of the trials, and were often presented with a favorable twist, Wired reports.

This kind of biased reporting could result in doctors recommending expensive new drugs that aren't better than what was already on the market. But it can have more dangerous consequences as well: The elevated heart-attack risk that has been shown to accompany Vioxx use was glossed over in Merck's propaganda-esque studies, leading to an estimated 27,000 deaths. The FDA maintains that it approves drugs based on application data, not medical papers, and that it makes its finding public.

Vioxx, an anti-inflammatory drug from Merck, doubled heart-attack risk, killing an estimated 27,000 people. The company's studies had glossed over the elevated risk.
Vioxx, an anti-inflammatory drug from Merck, doubled heart-attack risk, killing an estimated 27,000 people. The company's studies had glossed over the elevated risk.   (AP Photo/Daniel Hulshizer, File)
The cholesterol-lowering drug Vytorin, from pharmaceutical companies Merck & Co. and Schering-Plough Corp., has been shown to be ineffective, not something mentioned in its trial studies.
The cholesterol-lowering drug Vytorin, from pharmaceutical companies Merck & Co. and Schering-Plough Corp., has been shown to be ineffective, not something mentioned in its trial studies.   (AP Photo/Schering-Plough Corp., HO)
Moncef Slaoui, chairman of Research and Development at GalaxoSmithKline, testifies on Capitol Hill in Washington, before a committee hearing on the diabetes drug Avandia.
Moncef Slaoui, chairman of Research and Development at GalaxoSmithKline, testifies on Capitol Hill in Washington, before a committee hearing on the diabetes drug Avandia.   (AP Photo/Susan Walsh)
« Prev« Prev | Next »Next » Slideshow

The main thing that jumped out at me was the addition and deletion of primary outcomes. To find that one disappeared from a paper, or just appeared in a paper, is pretty amazing to me. - Lisa Bero, a UC, San Francisco health policy expert and study co-author

« Prev« Prev | Next »Next » Slideshow
0 comments
VIEWING:
 
LEAVE A
COMMENT
Comment Policy
Facebook ConnectPost this comment to Facebook?

After connecting you will have the option to post your comment on your Facebook profile.